Navigating Regulatory Affairs for Long-Term International Success

Successfully expanding into international markets can be a complex endeavor. For Chinese biotech companies that have completed Phase I trials and are eager to broaden their research into the U.S., the path forward is filled with both opportunity and regulatory intricacy. At Phazemos, we understand the unique challenges faced by these firms and provide expert guidance to help them establish a solid foothold in the U.S. market.